Bayer's Kovaltry receives FDA approval to treat haemophilia A

German pharmaceutical company Bayer has received approval from the US Food and Drug Administration (FDA) for Kovaltry Antihemophilic Factor (Recombinant) for the treatment of children and adults with haemophilia A.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news